The Bredesen Protocol is a holistic, personalised dietary and lifestyle programme for halting and reversing cognitive decline, dementia and Alzheimer's Disease by optimising brain health. It was developed by Dr Dale Bredesen, MD – a US based researcher of neurodegenerative diseases. The programme represents Functional Medicine at its very best, since it aims to identify the root cause(s) for an individual's cognitive decline and tackles these in a highly targeted way.
Here’s some more information on the Bredesen protocol.
Practitioners interested in incorporating the Bredesen Protocol into their clinical practice should sign up for Apollo Health’s ReCODE 2.0 training. This will provide the tools needed to manage the overall care, including identification of the specific drivers of cognitive decline and development of a treatment plan using the Bredesen Protocol. The training is suitable for functional health practitioners such as Doctors, Nutritionists, Osteopaths and Chiropractors.
Bredesen Protocol practitioners are in high demand, and the specialised knowledge and expertise delivered via the Apollo Health training, will provide them with a launchpad for ascending as leaders in the field of treating, preventing, and reversing cognitive decline.
More information about the training and how to enrol.
Introducing the ReCODE Program
The ReCODE program relies upon the ReCODE report — a highly individualised evaluation of your cognitive health analysed by a software program created by Dr. Dale Bredesen and his team at Apollo Health. The report includes information on which of the six subtypes are contributing to a client’s symptoms of cognitive decline and provides detailed, personalised instructions to specially address whatever is driving symptoms, including nutritional, lifestyle, hormone, and supplement recommendations. The report is generated following completion of lab tests available via Colabs in Europe.
Introducing the PreCODE Program
The PreCODE Program is designed for cognitively intact individuals wanting to optimise their brain health and prevent cognitive decline. It has been designed for adults of any age with a family history of dementia, risk factors such as pre-diabetes or inflammation, and for anyone over 45 years of age.
The Science Behind PreCODE and ReCODE
PreCode is the creation of Dr Dale Bredesen, an internationally recognised expert in the mechanisms of neurodegenerative diseases, with over 30 years of research into the causes of Alzheimer’s disease. He has shed light on the variety of “insults” resulting from modern society that lead to neuro-degeneration and interfere with the preservation of brain health. These insults, such as inflammation, insulin resistance, lack of trophic support, resistance to specific pathogens in our environment, and multiple other factors contribute to cognitive decline and occur slowly and insidiously over time providing a decade(s) long prodromal period in which we can intervene.
Inspired by Dr Bredesen’s ground-breaking ReCODE program for reversing cognitive decline, the PreCODE protocol provides patients with the basic tools they need to proactively defend themselves against these insults and optimise brain health for enhanced cognition.
CoLabs and PreCODE and ReCODE testing
Colabs is excited to support practitioners and their patients wishing to follow the PreCODE and ReCODE programmes, by bringing both comprehensive diagnostic panels to the European market. All key biomarkers in the PreCODE and ReCODE datasets can now be found in one place and at a competitive price – thereby reducing testing logistics for the practitioner and making a complete laboratory workup an affordable option for patients.
For total practitioner flexibility we have made available several adjuncts to the basic PreCODE panel which can be bolted on as needed, to cater for individual patients’ presentations and budgets.
In addition Colabs can also support practitioners access neurological scanning such as volumetric MRI and FDG Pet Scans. Please contact us for further detail on this.
This core panel allows for a full evaluation of key potential genetic, metabolic, endocrine and toxic contributors to cognitive decline.
Q500/501 Re:CODE Markers included: FT3, FT4, RT3, TSH, Cortisol AM, DHEA-S, Oestradiol, Progesterone, Testosterone, Copper, Ferritin, Glutathione (RBC), Magnesium (RBC), Insulin, Vitamins B9 (Folate), B12, D, E, Zinc, Homocysteine, APOE, Arsenic, Lead, Mercury, FBC, Urea, Comprehensive Metabolic Panel, HDL, LDL, Total Cholesterol, Triglycerides, HbA1C, MMP9, Hs-CRP.
Q505 Pre:CODE Markers included: APOE status, Homocysteine, Fasting insulin, Lipid Panel (cholesterol total, trigs, HDL-C, LDL-C, Cholesterol/HDL Ratio, Non-HDL cholesterol), Comprehensive Metabolic Panel, Complete Blood Count (CBC), Hs-CRP, TSH, Vitamin D, Ferritin.
These ‘bolt-on’ panels allow for an evaluation of those patients with a suspected mould / biotoxin component to their cognitive decline.
Q100 Markers included: ACTH, Total IgE, Osmolality, VIP, Cortisol AM, Anti Cardiolipin antibodies, VEGF, C4a, Copeptin, Leptin, MMP9, TGFb1, aMSH
Q150 Markers included: Total IgE, Osmolality, VEGF, C4a, MMP9, TGFb1, aMSH
This ‘bolt-on’ panel allows for an evaluation of those patients with a history of Lyme disease (or possible exposure to a tick born illness), as a contributory factor to their cognitive decline.
Markers included: Borrelia ELISA IgG/IgM, reflex to Western Blot